Return to the home page of the Diabetes Monitor
Federal Bureau of Prisons Clinical Practice Guidelines for diabetes (part 3)
Advertisement


 

go to home page read about us contact us read our disclaimer go to the index read our mission statement read our privacy policy search our website go to the site map find out what's new


The Federal Bureau of Prisons Clinical Practice Guidelines for Diabetes provide recommendations for the medical management of Federal inmates with diabetes mellitus.

Part 3


On this page:

ATTACHMENTS

Appendix 1: Treatment Goals for Nonpregnant Inmates
Appendix 2: The Food Guide Pyramid
Appendix 3: Oral Agents for the Treatment of Type 2 Diabetes
Appendix 4: Type 2 Diabetes - Combination Drug Therapy Options
Appendix 5: The Carville Diabetic Foot Screen
Appendix 6: Progress Note: Diabetic Foot Examination*
Appendix 7: Recommendations for Chronic Care Clinic Monitoring
Appendix 8: Keys to Diabetes Control
Appendix 9: Inmate Fact Sheet (Diabetes)
Appendix 10: Resources (Diabetes)
Appendix 11: Provider Self Assessment (Management of Diabetes)

REFERENCES




[Top]

Appendix 1 TREATMENT GOALS FOR NONPREGNANT INMATES WITH DIABETES

Normal
Goal
Intervention
Plasma values
Average preprandial glucose (mg/dl) <110 90-130 <90/>150 Average bedtime glucose (mg/dl) <120 110-150 <110/>180 Whole blood values
Average preprandial glucose (mg/dl) <100 80-120 <80/>140 Average bedtime glucose (mg/dl) <110 110-140 <100/>160 A1C(%)
<6 <7 >8 *Adapted from American Diabetes Association guidelines, 2002

[Top]

Appendix 2

[see diabetes food pyramid]

[Top]

Appendix 3 Oral Agents for the Treatment of Type 2 Diabetes

Agent Initial Dose & Treatment Maximum Dose Initial Elderly Dose Side Effects Drug Interaction

Second Generation Sulfonylureas

Glyburide (DiaBeta, Micronase)

2.5 - 5 mg/day; increase dose by 2.5- 5 mg no more often than every 7 days 20 mg 1.25-2.5 mg hypoglycemia and weight gain alcohol; coumarin; zole antifungals; asparaginase; corticosteroids; thiazide diuretics; lithium; beta blockers; cimetidine; ranitidine; cyclosporine; quinolones; MAO inhibitors; chloramphenicol; octreotide; pentamidine

Glyburide, microcrystalline (Glynase) 1.5 -3 mg/day; increase by < 1.5 mg weekly if needed 12 mg 1.25 mg hypoglycemia and weight gain same as above

Glipizide, short-acting (Glucotrol)

5 mg/day, 30 min before breakfast; increase dose by 2.5 - 5 mg a week as needed 40 mg give bid when dose reaches 15 mg 2.5 - 5 mg hypoglycemia and weight gain same as above

Glipizide, extended release (Glucotrol XL)

5 mg/day at breakfast; increase dose by 2.5 - 5 mg at 3 month intervals based on HbA1C 20 mg 2.5 mg hypoglycemia and weight gain same as above

Glimepiride (Amaryl)

1-2 mg daily with breakfast or first main meal; increase at 1-2 mg increments every 1-2 weeks as needed 8 mg once daily 0.5 - 1 mg hypoglycemia and weight gain same as above

Biguanides

Metformin (Glucophage) **Contraindications to metformin therapy: elevated creatinine (>1.4mg/dL in women or >1.5mg/dL in men), or a creatinine clearance < 60mL/min in the elderly; history of renal insufficiency, hepatic dysfunction, or serious cardiovascular or pulmonary compromise 500 mg with a meal; on the basis of patient's tolerance to metformin and glycemic response, increase dosage by 500 mg/day at weekly intervals, adding a dose to another meal; tid dosing not required for efficacy but may decrease GI complaint; doses >1000 mg/day with meals will likely be needed for therapeutic effect as monotherapy; doses >2000 mg/day have little added benefit. 2550 mg/day (850 mg tid); OR 2500 mg/day (500 mg tab) 500 mg nausea and diarrhea that usually subside over 1 week may limit rate of dose increase; hypoglycemia only if metformin is given with sulfonylurea or insulin alcohol - cimetidine - amiloride - digoxin - morphine - procainamide - quinidine - ranitidine - triamterene -trimethoprim - vancomycin - furosemide - calcium channel blocking agents especially nifedipine *withhold 48 hours prior to and following surgery or IV contrast
x-ray studies.

Alpha-Glucosidase Inhibitors

Acarbose (Precose)

25 mg tid with first bite of meals; lower dose may be needed if gastrointestinal distress is noted. Increase dose to 50 mg tid with meals after 4-8 weeks 100 mg tid with meals or 50 mg tid with meals (In patients < 60 kg) 25 mg diarrhea (33%) abdominal pain (12%) flatulence (77%) * serum transaminase elevations may occur at doses >50mg tid. absorbents, intestinal agents such as activated charcoal digestive, enzyme preparations containing carbohydrate - splitting enzymes such as amylase or pancreatin

Thiazolidinediones

Rosiglitazone (Avandia) 4 mg qd or 2 mg bid; increase to 8 mg qd or 4 mg bid in 12 weeks as needed 8 mg/day 2 mg edema; fluid retention may cause or exacerbate CHF. erythromycin- calcium channel blocker- corticosteroids -cyclosporine - hmg coa reductase inhibitors - triazolam - trimetrexate - ketoconazole - itraconazole

Pioglitazone (Actos) 15 or 30 mg qd; increase to 45 mg qd monotherapy or 30 mg qd as combo therapy 45 mg/day monotherapy; 30 mg/day combo therapy 15 mg edema * decreases oral contraceptive efficacy same as above

Meglitinides

Repaglinide (Prandin) 0.5 mg with each meal if HbA1C <8%, 1 - 2 mg with each meal if HbA1C >8%; Increase by 1 mg weekly as needed 4 mg with meals (max 16 mg total per day) 0.5 mg hypoglycemia and weight gain *contraindicated in moderate-severe hepatic dysfunction
beta- adrenergic blocking agents; drugs metabolized by the cytochrome p450 system; erythromycin; ketoconazole; miconazole; sulfonamides; MAO inhibitors; NSAIDS; anticoagulants (warfarin derivatives)

Nateglinide (Starlix) 60 mg, 1 to 30 min before each meal if HbA1C < 8%; 120 mg if > 8% 180 mg tid 60 mg hypoglycemia and weight gain same as above

[Top]

Appendix 4 Type 2 Diabetes Mellitus - Combination Drug Therapy Options

Sulfonylurea + Biguanide
Sulfonylurea + Insulin
Biguanide + Insulin
Sulfonylurea + Alpha-glucosidase inhibitor
Sulfonylurea + Biguanide + Insulin*
Biguanides + Alpha-glucosidase inhibitor*
Thiazolidinedione + Insulin
Biguanide + Meglitinide
Rosiglitazone or Pioglitazone + Sulfonylurea
Alpha-glucosidase inhibitor + Insulin*
Sulfonylurea + Biguanide + Thiazolidinedione*
* Denotes less frequently used therapy/less studied therapy

[Top]

Appendix 5 THE CARVILLE DIABETIC FOOT SCREEN

This appendix was adapted directly from the LEAP program at the Hansen's Disease Center, Carville, Louisiana. A BOP-designed progress note for documenting these examinations is found in Appendix 6, a Word Perfect version of the Form 600 with the outline of the examination overprinted. This form may be printed and inserted in chronological order in section 1 of the Inmate Medical Record.

Section I

In the first section of the Foot Screen, the five questions can be answered in the Yes or No blank with an R, L, or B to indicate a positive or negative finding in the right, left, or both feet.

1. Has there been a change in the foot since the last evaluation?
On a first visit, enter N/A unless the inmate has noticed a change in strength or sensation within the past year. If that is the case, then check Yes. The purpose of this question is to determine from the inmate if he/she has perceived a change in the strength or sensation of their feet. Any change is significant in a foot screen. For example, an improvement in the inmate's perception of sensation could be a sign that the inmate is having a reversal of some of the neuropathic changes. Alternatively, if the inmate perceives a change for the worse, this could be a sign of worsening of the neuropathy.

2. Is there a foot ulcer now, or history of foot ulcer?
The purpose of this question is to determine if the inmate has now, or has ever had an ulcer on the foot. A positive history of a foot ulcer places the inmate permanently in Risk Category 3. Once an inmate has ulcerated, he or she is always at an increased risk of developing another foot ulcer. The inmate is also at risk of developing a progressive deformity of the foot and ultimately amputation of the lower extremity.

3. Does the foot have an abnormal shape?
This is determined by inspecting the general shape of the inmate's foot. Conditions to consider include: foot drop, eversion or inversion deformity, partial or complete amputations of the foot or toes, clawed toes, bunions, and especially a "Charcot Foot." A Charcot Foot is a foot which is moderately to severely deformed as a result of insensitivity and repeated injury. Fractures in an insensitive foot frequently fail to heal properly and can progress to the so-called boat shaped foot. These feet are at extreme risk of amputation and require immediate, expert care. A patient with a Charcot Foot is always in Category 3.

4. Is there weakness in the ankle or foot?
Unless the inmate has an open ulcer or infection of the foot, a rough estimate of strength can be made by asking the inmate to walk alternately on their heels and then on their toes.

5. Are the nails thick, too long, or ingrown?
If severe nail problems are present or if there is uncertainty about the vascular status of the toes, refer the inmate to an appropriate evaluator.

Section II

In the next section of the foot screen, the examiner does a sensory exam of the foot using the 10 gram monofilament and records the findings on the form in the circles on the foot drawing. There are ten places on each foot that are routinely tested. If the inmate can feel the filament, put a "+" in the appropriate circle. If they cannot feel it, put a "-". The sensory exam should be done in a quiet and relaxed setting, where the inmate can lie down. The inmate should not watch while the examiner applies the filament.

Section III

Next, examine the foot and record the problems identified by drawing or labeling as appropriate on the Foot Screen form. If there are callouses, pre-ulcerative lesions (a closed lesion, such as a blister or hematoma) or open ulcers, draw or describe them as accurately as possible. Then, draw in and label areas that are significantly red, warm (warmer than the other parts of the foot or the opposite foot), dry or macerated (friable, moist, soft tissue).

Section IV

This is the vascular assessment. Vascular studies are an important part of a foot evaluation in patients with diabetes and should at least include the palpation of pulses. More extensive evaluations such as doppler studies and angiography should be considered on a case by case basis.

Section V

Footwear is discussed under the appropriate Risk Category below.

Section VI

Risk Categorization: The accurate categorization of inmates into their respective Risk Category is a key element in the Foot Screen. The higher the Risk Category, the higher the risk an inmate has of recurrent foot ulceration, progressive deformity and ultimately, amputation of the foot.

Category 0: No loss of protective sensation. This is a patient who has essentially no risk of developing foot complications as a result of their disease. This patient does not need special footwear.

Category 1: Loss of protective sensation, no deformity or history of plantar ulceration. This patient has lost sensation to the point that they are defined as not having "protective sensation." These patients cannot feel the 10 gram monofilament and therefore cannot trust their sensation to prevent injury. The patients in this and the following two categories should never walk barefoot. They do not have enough sensation to prevent injuring themselves (e.g. as a result of stepping on sharp objects). Patients in this and the following two categories need to pay special attention to the fit and style of their shoes and should avoid pointed toed shoes or high heels. Category 1 patients do not need "custom" shoes. They usually do well in a jogging shoe or a well-fitting street shoe.

Category 2: Loss of protective sensation and deformity, no history of plantar ulceration. This patient, in addition to the loss of protective sensation, also has additional abnormalities, but has not progressed to the point of ulceration (current or past). They may need extra depth shoes with custom molded insoles to accommodate deformity of their feet. These patients can frequently wear a jogging shoe with a soft insert.

Category 3: History of plantar ulcer. This patient has loss of protective sensation and has progressed to the point of plantar ulceration (current or past). They will need extra depth shoes with soft molded inserts to accommodate any deformity of their feet. They may need custom-made shoes to manage their foot problems once their ulcer is healed.

FILAMENT APPLICATION INSTRUCTIONS
The sensory testing device used with the Foot Screen is a nylon filament mounted on a holder that has been standardized to deliver a 10 gram force when properly applied. Hansen's disease researchers have shown that a patient who can feel the 10 gram filament in selected sites are not at increased risk to develop ulcers.

1. Sites to be tested:
Dorsal foot: center of the top of the foot
Plantar foot:
(1) center of the heel pad
(2) medial arch
(3) "ball" of foot
(4) over distal 3rd metatarsal head
(5) over distal 5 metatarsal head
(6) over proximal 5th metatarsal
2. Apply the filament perpendicular to the skin's surface.
3. The approach, skin contact and departure of the filament should be approximately 1 1/2 seconds duration.
4. Apply sufficient force to cause the filament to bend.
5. Do not allow the filament to slide across the skin or make repetitive contact at the test site.
6. Randomize the selection of test sites and time between successive tests to reduce the potential for patient guessing.
7. Ask the patient to respond "yes" when the filament is felt and record the responses.
8. Apply the filament along the perimeter of and NOT on an ulcer site, callus, scar or necrotic tissue.

[Top]

Appendix 6

(Insert copy of 600 form with Diabetic Foot Examination, reprinted-front and back)
[We cannot locate a copy of this form on the Internet. Sorry.  —The Editors.]

[Top]

Appendix 7 Recommendations for Diabetic Chronic Care Clinic Monitoring

Patient Evaluation / Routine Exam - SOAP Format
S: < Observations and patient complaints >
O: Vital signs : blood pressure, pulse, respiration rate, temperature, weight, height HEENT: (include fundoscopic exam and neck evaluation) Lungs/Heart: Abdomen: Extremities/ Peripheral pulses / Neuropathy / Visual Foot Examination Labs, X-Rays, Other Studies
A: Assessment, Analysis of data, Diagnosis
P: Therapeutic regimen
Diagnostic studies
Education - adherence to all self care aspects, exercise evaluation, follow-up of referrals, smoking cessation

Procedure, Test, Examination Baseline Visit Quarterly Visit Semiannual Visit Annual Visit
Routine physical exam x x    
Fasting blood sugar (record results of self-monitoring where applicable) x x    
Fasting complete metabolic panel (electrolytes, creatinine, total cholesterol) x     x
Fasting Lipid profile *more often if managing a lipid disorder, less often if low risk x     x
HBA1C x (x) if treatment changes, or clinically indicated x  
Urinalysis (dipstick) x     x
Urine microalbumin x if standard dipstick urinalysis is negative for protein     x if standard dipstick urinalysis is negative for protein
Ophthalmologic exam (preferably dilated) x     x
Fundoscopic exam (performed by primary provider) x x    
Foot Exam: visual x x   x
Foot Exam: monofilament x     x
EKG x      
Fasting or random glucose ( finger stick) monitoring - methods and times must be determined on a case-by-case basis depending on the medical needs of the inmate and severity of the condition.

[Top]

Appendix 8 Keys to Diabetes Control

Years ago, the diabetic diet was strict and boring. Today, you do not need special foods; in fact, the foods that are good for you are good for everyone. Diabetes can not be cured, but it can be controlled so that you can lead a normal life and when your diabetes is in good control, complications may be prevented or delayed. There are three keys to controlling diabetes: 1) Diet - weight control or maintenance; 2) Exercise; and 3) Medication - pills or insulin. All three are equally important. Your food intake and activity needs to balance with your medication for good blood glucose control. By making the proper food choices, exercising, and taking prescribed medication throughout the day, you will be able to maintain a healthy weight and blood glucose control. Steps to Control Blood Glucose
  • Eat a wide variety of foods every day: Increase high fiber foods such as: grains, beans, vegetables, and fruits to fill you up.
  • Limit concentrated sweets such as: sugar, honey, jelly, syrup, cakes, cookies, candy, ice cream, pies, pastries, regular soda or kool-ade. Concentrated sugars do not cause diabetes, and do notneed to be totally avoided. However, they are concentrated calories - the more calories you eat, the higher your blood glucose.
  • Limit fats such as: butter, margarine, cheese, fried foods, cream soups, gravy, salad dressings, mayonnaise, and breakfast meats (bacon, sausage, etc.).
  • Control portion sizes: Too much of even the right foods can also cause high blood glucose. If you want to lose weight, cut down on portion sizes.
  • Never skip meals: Eat all three meals and include snacks as needed. Eat at about the same time every day.
  • Exercise: Increase your activity level (as permitted by your doctor). This will decrease your blood glucose level.
  • Monitor your weight: Weigh yourself only once a week to determine if your diet is effective. If you are overweight, a weight loss of 1-2 pounds per week is a good goal.
  • Medication: If you take pills or insulin for your diabetes, always take your medication as your doctor has recommended.

[Top]

Appendix 9 INMATE FACT SHEET (Diabetes)


1. What is diabetes?
Diabetes is a chronic disease for which there is no cure. It can be controlled by a combination of diet, exercise, and medical care. Diabetes means having too much sugar (glucose) in the blood. In people who have diabetes, sugar builds up in the blood instead of going into the cells.

2. What are the symptoms of diabetes?
Most people with diabetes do not notice any symptoms. However, some symptoms of diabetes are:

  • Frequent urination
  • Increased thirst and increased hunger
  • Unexplained weight loss
  • Weakness, fatigue, drowsiness
  • Wounds and cuts that heal slowly
  • Blurred vision or changes in vision
3. What puts you at risk for diabetes?
  • You are age 45 and older
  • You are a member of a high-risk ethnic group (African American, Hispanic/Latino, American Indian, Asian American, Pacific Islander)
  • You are overweight
  • You have high blood pressure (at or above 140/90)
  • You have a family history of diabetes
  • You have a history of diabetes during pregnancy
  • You weighed more than 9 pounds at birth 4. What are the complications of diabetes?
  • Eye damage - poor vision, retina damage, cataracts, glaucoma, blindness
  • Kidney damage - progressive failure may require hemodialysis or organ transplantation
  • Heart problems - damaged blood vessels leading to heart attacks and strokes
  • Nerve damage - problems with nerve sensations and moving muscles, loss of reflexes
  • Decreased ability to fight infections
  • Sores and ulcers of the legs and feet
5. How is diabetes controlled?
Diabetes is controlled by a combination of diet, exercise, and medication. Treatment goals are to keep blood sugar near normal, control blood pressure, lower cholesterol and fat levels, and lose weight or maintain a healthy weight. Research shows that keeping blood sugar as near to normal as possible means fewer complications of the disease. Strict control of blood sugar helps to prevent kidney failure, amputations, blindness, heart attacks, and stroke.

6. What are the symptoms of hypoglycemia (low blood sugar)?

  • Shakiness
  • Sweating and clammy feeling
  • Extreme fatigue
  • Hunger
  • Irritation or confusion
  • Rapid heart rate
  • Blurred vision

[Top]

Appendix 10 Resources (Diabetes)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
800 860-8747
www.niddk.nih.gov
National Diabetes Information Clearinghouse
800-860-8747
www.niddk.nih.gov/health/diabetes/ndic.htm
Centers for Disease Control and Prevention
877 232-3422
www.cdc.gov/diabetes
American Diabetes Association
800 342-2383
www.diabetes.org
American Dietetic Association
800 366-1655
www.eatright.org
National Kidney Foundation
800 622-9010
www.kidney.org

[Top]

Appendix 11 PROVIDER SELF-ASSESSMENT

(Management of Diabetes)

1. The optimal test to diagnose diabetes is which of the following?
A. Casual blood glucose B. Random blood glucose C. Fasting blood glucose D. Glucose tolerance test E. Glycosylated hemoglobin (A1C)

2. A normal plasma fasting blood glucose is defined as which of the following?
A. < 100 mg/dL B. < 105 mg/dL C. < 110 mg/dL D. < 115 mg/dL E. < 126 mg/dL

3. Diabetes is diagnosed by two plasma fasting blood glucose readings above or equal to
which value?
A. $ 110 mg/dL B. $ 117 mg/dL C. $ 120 mg/dL D. $ 126 mg/dL E. $ 130 mg/dL

4. Hemoglobin A1C levels are potentially affected by which of the following?
A. Eating chocolate cake the night before testing B. Running on a treadmill immediately before testing C. Drinking orange juice immediately before testing D. The stress of a car accident the week before testing E. Hemolytic anemia

5. The target A1C level for inmates with diabetes is which of the following?
A. < 9% B. < 8% C. < 7% D. < 6%

6. Which of the following agents can precipitate diabetes/glucose intolerance? A. Indinavir B. Pentamidine C. Risperidone D. Olanzapine E. All of the above

7. True or False: Metformin is an excellent choice for treating obese patients with type 2 diabetes, but should not be prescribed if the patient has significant renal insufficiency?

8. Which of the following drug combinations should not be prescribed for type 2 diabetes?
A. Pioglitazone and metformin B. Glyburide and repaglinide C. Metformin and glipizide D. Metformin and insulin E. Acarbose and glyburide

9. The LDL cholesterol goal for a diabetic patient is which of the following?
A. < 200 mg/dL B. < 130 mg/dL C. < 100 mg/dL D. < 75 mg/dL

10. Adequate blood pressure control for most patients with diabetes is which of the
following?
A. < 150/80 B. < 140/95 C. < 140/90 D. < 145/85 E. < 130/80

11. Which of the following statements is false regarding diabetic retinopathy?
A. Type 1 diabetics usually have evidence of retinopathy at initial diagnosis. B. Type 2 diabetics usually have evidence of retinopathy at initial diagnosis. C. Patients with retinopathy may be asymptomatic. D. Poorly controlled glucose is associated with retinopathy. E. Aspirin does not increase the risk of retinal hemorrhage.

12. A diabetic inmate presents to sick call with nausea, vomiting, and flank pain. He has hematuria and is dehydrated with a random blood glucose of 420. He is on metformin and is otherwise stable. His pain fails to resolve. Your urology consultant recommends IVP. An appropriate next step would be:
A. Hydrate/increase metformin B. Hydrate/continue metformin/add sliding scale insulin C. Hydrate/decrease metformin/add insulin D. Hydrate/discontinue metformin/add sliding scale insulin

13. An inmate stumbles and collapses at mainline waiting for the noon meal. He is clammy and sweaty, incoherent but conscious. You are the first responder and fortunately are his primary care provider. You know that he is a diabetic on insulin and acarbose with a longstanding history of heroin use. A fingerstick glucose confirms hypoglycemia. The Clinical Director arrives and you discuss the most appropriate next step:
A. Grab fruit juice from the chowline and administer orally B. IV narcan first, if no response give fruit juice C. Intravenous bolus of glucose (D50) D. Transfer to community emergency room

14. Which of the following is not routinely indicated for a 50 year old insulin-dependent diabetic with hypertension, proteinuria, and a family history of heart disease?
A. Aspirin B. Annual influenza vaccine C. Treatment for latent TB infection if PPD is 10 millimeters D. ACE inhibitor E. Beta-blocker

15. Diabetes is associated with which of the following?
A. Thyroid disease B. Protease inhibitor therapy for HIV C. Obesity D. Native American ethnicity E. All of the above

[Top]

PROVIDER SELF-ASSESSMENT ANSWERS

(Management of Diabetes)

1. Answer is C
2. Answer is C
3. Answer is D
4. Answer is E
5. Answer is C
6. Answer is E
7. Answer is TRUE
8. Answer is B
9. Answer is C
10. Answer is E
11. Answer is A
Retinopathy does not usually develop in type 1 diabetics until 5 years after the onset of disease.
12. Answer is D
Metformin can cause severe lactic acidosis in dehydrated patients and should be discontinued 48 hours prior to the use of IV contrast. This acutely ill inmate with poor oral intake is best managed with IV hydration and analgesics, discontinuation of metformin, insulin as needed, and an IVP to evaluate for nephrolithiasis if flank pain is unresolved.
13. Answer is C
The inmate is experiencing a typical hypoglycemic reaction. Oral administration of fruit juice is likely to be ineffective due to the blockage of absorption by acarbose. Intravenous administration of glucose ASAP is warranted, particularly with evidence of altered mental status that suggests a severe hypoglycemic reaction. Other treatment options include parenteral glucagon or oral glucose.
14. Answer is E
Beta-blockers can mask or prolong hypoglycemia and should be avoided in diabetic patients when feasible. Nevertheless, beta-blockers should be given to diabetics who have had a myocardial infarction since it reduces long-term mortality.
15. Answer is E

[Top]

REFERENCES

American Diabetes Association: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Diabetes Care, 2002;25:S5-S20.

American Diabetes Association: Standards of Medical Care for Patients With Diabetes Mellitus, Diabetes Care 2002;25:S33-S49.

Inzucchi, SE. Oral antihyperglycemic therapy for type 2 diabetes, JAMA 2002;287:360-372.

Drugs for diabetes, Treatment guidelines from the Medical Letter, M. Abramowicz, Editor, 2002;1:1-6.

Mattson JS and Cerutis RD. Diabetes mellitus: A review of the literature and dental implications, Compendium of Continuing Education in Dentistry, 2001;22(9):757-770.

Mokdad, AH. The continuing epidemics of obesity and diabetes in the United States, JAMA 2001;286:1195-1200.

Lower Extremity Amputation Prevention Program (LEAP) Program, Rehabilitation Branch, Gillis W. Long Hansen's Disease Center, Carville, LA.


From the Federal Bureau of Prisons
September 2002
http://www.bop.gov/news/PDFs/diabetes.pdf


Table of Contents | Part 1 | Part 2 | Part 3





Advertisements





  [Top]  
Webpage new at the DiabetesMonitor 17Apr2005
 
Advertisement
 


Return to the home page of the Diabetes Monitor Go to the index Search this website Go to the site map Read our copyright noticeRead our copyright notice Send us an e-mail at info@diabetesmonitor.com